Clinical Trial Update: Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 pediatric trial evaluating a triple combination of nanoparticle albumin-bound rapamycin, temozolomide, and irinotecan for recurrent or refractory solid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Tumors
• Malignant Pediatric Solid Tumors
• Solid Tumors

Drugs mentioned

• Camptosar (irinotecan)
• Nanoparticle Albumin-Bound Rapamycin (sirolimus (nanoparticle albumin-bound formulation))
• Temozolomide (Temozolomide)

Snippet

Sponsor: Children's Oncology Group | Conditions: Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 1 | Status: COMPLETED | Results posted: 2023-03-30